Web臨床雑誌外科 83巻6号 (2024年5月発行). JCOG0603試験の結果を客観的に評価すると,主要評価項目である無病生存期間(DFS)において術後補助化学療法(mFOLFOX6)群が手術単独群に優ったポジティブ試験であった.副次評価項目である全生存期間(OS)に … Web24 set 2024 · In the article accompanying this editorial, Kanemitsu et al 11 report the results of JCOG0603, a randomized trial of postoperative adjuvant modified FOLFOX (mFOLFOX6) versus surgery alone for resected CRCLM. These trials are difficult to conduct and the authors are to be congratulated for undertaking such an important study.
Capecitabine and Chemotherapy and Preoperative radiotherapy …
http://www.pieronline.jp/content/article/0016-593x/83060/675 Web20 mag 2024 · The JCOG0603 trial compared hepatectomy followed by modified fluorouracil, leucovorin and oxaliplatin (mFOLFOX6) with hepatectomy alone in CLM, and preliminary data were presented at the 2024 ... how medium makes money
大腸癌肝転移切除後患者を対象としたフルオロウラシル/l-ロイコ …
WebJCOG0603 is the latest offive phase III trials testing postoperative or perioperative chemotherapy for patients with CRC and resectable liver metastases (Table 1).1-5 With the only exception of ENG (EORTC/ NCIC CTG/GIVIO), the results of which are anyway difficult to interpret because of its premature dis- Web肝切除のみと、切除後にFOLFOX療法を行った場合とを比較したJCOG0603試験がありますが、FOLFOX群の8コースの完遂率が非常に悪く、現在試験がストップしています。 … how medicine solutions are made